Eurofins Scientific Shares Climb 3.67% Ahead of Key Earnings Release

Short-Term Resistance and Market Dynamics

Today's bullish acceleration allows Eurofins Scientific to approach its 50-day moving average, located at €65.74, which acts as a short-term resistance. The stock is now clearly above its 200-day moving average (€63.39), crossed in recent sessions, indicating an improvement in medium-term dynamics. The RSI, at 44, remains in the neutral zone and does not signal an overbought condition, leaving room for potential further gains before reaching technical tension levels. Over the past week, the stock has gained 6.49%, and its performance over the past year exceeds 31%. The most relevant support level is at €60.76, recently tested during the pullback phase observed in recent weeks. Today's movement is part of a general rebound in the CAC 40, which is up 2.08% in the session, as well as the SBF 120, up 2.10%.

Financial Calendar Enters Critical Phase

Eurofins Scientific's financial calendar is entering a critical phase. The group will publish its 2025 annual results on April 10, less than ten days away, before the annual general meeting scheduled for April 23. These upcoming events could fuel repositioning movements in the stock in the coming sessions. The health and life sciences services sector shows a positive tone this Wednesday: among comparable stocks, UCB is up 3.17% while Sanofi gains 0.42%. Eurofins Scientific's monthly volatility remains contained at 7.72, and a negative beta of -0.12 illustrates the stock's low correlation with major indices, a profile that may be of interest in a market environment marked by a VIX at 31.05, indicating high stress on global markets. The 2026 half-year results are expected on September 18.